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Abstract
Currently, five classes of drug are approved for the treatment of pulmonary arterial hypertension (PAH): phosphodiesterase 5
inhibitors (PDE5i); endothelin receptor antagonists; prostacyclin analogs; the IP receptor agonist selexipag; and the soluble
guanylate cyclase (sGC) stimulator riociguat. For patients with inoperable or persistent/recurrent chronic thromboembolic pul-
monary hypertension (CTEPH), riociguat is currently the only approved pharmacotherapy. Despite the development of evidence-
based guidelines on appropriate use of specific drugs, in clinical practice patients are often prescribed PAH-targeted therapies off
label or at inadequate doses.
PDE5i are the most often prescribed class of drugs as initial therapy, either alone or in combination with other drug classes.
However, a proportion of patients receiving PAH therapies do not reach or maintain treatment goals. As PDE5i and riociguat target
different molecules in the nitric oxide-sGC-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling pathway, for patients with
PAH without an initial or sustained response to PDE5i, there is a biological rationale for switching to riociguat. However, robust
data from randomized controlled trials on the safety and efficacy of switching are lacking, as is formal guidance for clinicians. Here
we review studies of sequential combination therapy, and trial data and case studies that have investigated switching between PAH-
approved therapies, particularly from PDE5i to riociguat in patients with PAH with an insufficient response to PDE5i, and in
patients with CTEPH who were receiving off-label treatment. These studies summarize the current evidence and practical real-life
experience on the concept of switching treatments.
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Introduction
Pulmonary hypertension (PH) is a progressive disease that
leads to pulmonary arteriolar vasoconstriction, right-ventri-
cular overload, and ultimately death. Pulmonary arterial
hypertension (PAH) is characterized by reduced levels of
the vasodilators nitric oxide (NO), cyclic guanosine mono-
phosphate (cGMP), and prostacyclin, and overexpression of
the vasoconstrictor endothelin. This results in increased
vascular tone, and promotes vascular remodeling and
the progressive destruction of the pulmonary vascular
bed. Chronic thromboembolic pulmonary hypertension
(CTEPH) is caused by obstruction of the pulmonary
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vasculature by residual organized thrombi, leading to
increased pulmonary vascular resistance (PVR), progressive
PH, and ultimately right ventricular failure.1–3
Five classes of drug are approved for the treatment of
PAH, targeting three signaling pathways (Fig. 1):4–7 prosta-
cyclin analogs (PCAs) epoprostenol, iloprost, treprostinil,
and beraprost; the IP receptor agonist selexipag;
the endothelin receptor antagonists (ERAs) bosentan,
ambrisentan, and macitentan; the phosphodiesterase
(PDE5) inhibitors (PDE5i) sildenafil and tadalafil; and the
soluble guanylate cyclase (sGC) stimulator riociguat, also
approved for patients with inoperable CTEPH or persist-
ent/recurrent CTEPH after surgery.
Impairment of the NO sGC-cGMP signaling pathway
(Fig. 2) is central to the pathogenesis of PAH and
CTEPH,8–10 where endothelial dysfunction leads to
impaired NO synthesis.10–14 The progression of PAH and
CTEPH also correlates with low NO production.
The purpose of this review is to provide a summary of
published experience of trials and case studies that have
investigated switching between approved PAH therapies,
particularly switching within the NO pathway in patients
with PAH and switching from off-label therapies to rioci-
guat in patients with CTEPH, and an overview of the
options for sequential combination therapy. Given that
switching patients from PDE5i to riociguat is already
taking place in clinical practice despite a lack of guideline
recommendations, we also provide some cautionary notes
on best practice.
Methods
To summarize a broad review of trials and case studies, a
PubMed literature search was performed using the following
search terms: ‘‘pulmonary arterial hypertension,’’ ‘‘pulmon-
ary arterial hypertension’’ AND ‘‘transition,’’ and ‘‘pulmon-
ary arterial hypertension’’ AND ‘‘switch.’’ To identify
studies of combination therapy, we searched for the follow-
ing drug names: riociguat, sildenafil, tadalafil, bosentan,
ambrisentan, macitentan, selexipag, epoprostenol, treprosti-
nil, iloprost, and beraprost.
Current treatment strategies for PAH
PDE5i and riociguat both target the NO-sGC-cGMP sig-
naling pathway to promote vasodilation with different
mechanisms of action (MoAs) (Fig. 1).6 PDE5 deactivates
and degrades cGMP, is abundantly expressed in pulmonary
Fig. 1. Mechanisms of action of approved classes of PAH-targeted therapies.6 cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine
monophosphate; endothelin receptor antagonists (ERA), endothelin receptor A; ETRB, endothelin receptor B; IP, prostacyclin; NO, nitric oxide;
PDE5, phosphodiesterase type 5; PH phosphodiesterase 5 inhibitors (PDE5i); pulmonary hypertension; PKA, phosphate kinase A; PKG, cGMP-
dependent protein kinase; RV, right ventricular; sGC, soluble guanylate cyclase.
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vasculature, and is upregulated in PAH. PDE5i occupy the
catalytic site on PDE5, blocking degradation of cGMP
(Fig. 1).6,15 However, the MoA of PDE5i is dependent on
endogenous NO bioavailability, and evidence suggests that
NO and intracellular levels of cGMP are depleted during the
progression of PAH, which could render PDE5i less effect-
ive. This may explain why some patients do not have a suf-
ficient sustained response to PDE5i. Riociguat has a dual
MoA; it sensitizes sGC to endogenous NO and directly
stimulates sGC via a second binding site, independent of
NO, and has been shown to increase sGC activity regardless
of NO and cGMP levels, resulting in increased cGMP.
ERAs, PCAs, and selexipag target different pathways.
ERAs prevent endothelin-1 (ET-1)- mediated vasoconstric-
tion by blocking the binding of ET-1 to ET-1 receptors
(Fig. 1), which are upregulated in PAH. PCAs are synthetic
analogs of the pulmonary vasodilator prostacyclin (also
known as prostaglandin I2) and selexipag is a high-affinity
agonist of the human IP receptor. In PAH, prostacyclin
synthase is downregulated and thus, prostacyclin levels are
decreased (Fig. 1).
Medical therapy may be prescribed as monotherapy or,
alternatively, as initial or sequential combination therapy.
With combination therapy, multiple signaling pathways
involved in the pathogenesis of the disease may be targeted.
Initial combined therapy with ambrisentan and tadalafil is
recommended in the 2015 European Society of Cardiology/
European Respiratory Society (ESC/ERS) guidelines, fol-
lowing the results of the AMBITION study. However, sev-
eral other studies of sequential combination therapy with
bosentan and a PDE5i did not show a significant effect,
possibly due to pharmacokinetic interaction (Table 1).17–20
Macitentan added to PAH background therapy (mostly sil-
denafil) was shown to be effective in a subgroup analysis of
the SERAPHIN study,21 as was selexipag added to back-
ground ERA or PDE5i in the GRIPHON study.22 Similarly,
riociguat added to existing ERA treatment was shown to be
effective in the PATENT-1 and -2 studies, and is recom-
mended in the 2015 ESC/ERS treatment guidelines.4,23,24
An overview of studies of sequential combination therapy
is given in Table 1.
The concomitant administration of PDE5i and riociguat
is contraindicated due to the risk of systemic hypotension.
For patients already receiving an ERA and either a PDE5i
or riociguat, a PCA or IP receptor agonist may be admin-
istered. Although triple combination therapy has the advan-
tage of acting on three different molecular targets, it also
increases pharmacologic complexity and the potential risk
of adverse events (AEs), and may lead to increased drug-
related healthcare costs. The addition of PCAs or selexipag
to an existing treatment regimen may cause additional side
effects such as headache, flushing, and jaw pain, and the
intravenous administration of PCAs carries the risk of
sepsis and embolic phenomena.
PDE5i are the most frequently prescribed treatment for
PAH, either as monotherapy or combination therapy.
However, clinical data indicate that 20–60% of patients
receiving PDE5i do not reach or maintain treatment goals
as set out in the 2015 ESC/ERS guidelines. Furthermore, in
AMBITION, 73% of patients with PAH receiving tadalafil
Fig. 2. The role of the NO signaling pathway in PAH and CTEPH pathogenesis16 (amended from Buglioni and Burnett. Annu Rev Med 2016; 67:
229–243). cGMP, cyclic guanosine monophosphate; GC-A, particulate guanylate cyclase A; GTP, guanosine triphosphate; NO, nitric oxide; NOS,
nitric oxide synthase; PDE, phosphodiesterase; PKG, cGMP-dependent protein kinase; sGC, soluble guanylate cyclase.
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as monotherapy, and 61% of patients receiving combined
ambrisentan and tadalafil, did not achieve the secondary
composite endpoint of satisfactory clinical response at
week 24. In the SERAPHIN study of macitentan in PAH,
the morbidity/mortality event-free survival of patients
receiving PDE5i monotherapy was approximately 50% at
three years.
The 2015 ESC/ERS treatment guidelines advise that the
treatment objective for patients with PAH is to achieve a
low-risk status, indicated by stable, non-progressive disease,
an approach supported by analyses of registry data. Patients
who do not reach or maintain a low-risk status are described
as having an insufficient response to treatment; the current
treatment guidelines recommend sequential addition of oral
therapies and then the addition of a prostanoid. However,
as a direct stimulator of sGC, riociguat targets a different
molecule in the same signaling pathway as PDE5i. For
patients without a sustained response to PDE5i, there is
therefore a biological rationale for switching to riociguat
in this setting to augment pharmacological effects and
lower risk. However, data are scarce on switching between
drug classes in PAH, including riociguat data, and the
majority of studies have focused on switching within
a drug class, e.g. from parenteral to inhaled prostanoids.
The concept of switching to riociguat from a PDE5i is an
attractive approach, particularly in patients at low/inter-
mediate risk and not rapidly deteriorating, to avoid therapy
complexity, mitigate overlapping side effects, and minimize
costs. Furthermore, in adults, switching to riociguat does
not preclude subsequent escalation to triple therapy.
However, further evidence to support this concept is still
required and it is important to remember that switching
between classes is not included in the 2015 ESC/ERS
guidelines.
Studies of switching between PAH-approved therapies
Multiple studies have evaluated switching to PAH therapies
other than riociguat, switching within a drug class, and from
one drug class to another (Table 2). However, switching
between drug classes is not recommended by the guidelines
due to the lack of randomized controlled trial (RCT)-based
evidence.4 PCAs are the longest-established therapy for
PAH, and switching between PCAs has been shown to be
well tolerated, prevent clinical deterioration, and maintain
functional status.25–27 In a retrospective assessment of
switching from intravenous epoprostenol to iloprost, after
one year 78% of patients remained on iloprost and 81%
were free from clinical worsening. Patients in these studies
were switched either because of drug-related AEs, because
clinical improvement during PCA therapy allowed a switch
to a non-intravenous formulation, or to achieve a more con-
venient administration schedule when switching between
inhaled PCAs.25–27 Other studies have assessed switching
from a prostanoid to an ERA such as bosentan28 or a
PDE5i such as sildenafil.29 These studies demonstrated a
prolonged and stable functional class, and improved 6-
minute walking distance (6MWD) and quality of life.28
After switching to sildenafil, approximately 70% of patients
maintained improved quality of life and improved 6MWD
for up to 3 months.29 Reasons for switching from a PCA to
an ERA included having met specific disease stability cri-
teria while receiving a PCA,28 and for those patients who
switched to a PDE5i, concerns over the availability of PCA
therapy in the study region.29 Switching within other drug
classes such as ERAs30 and PDE5i31–33 has also been eval-
uated and, although data are limited, exercise capacity and
World Health Organization functional class (WHO FC)
were sustained. The patients who switched from sitaxsentan
Table 1. Sequential combination therapy strategies tested in clinical randomized controlled trials.
Study name Combination Significant benefit Reference
PACES Epoprostenolþ sildenafil Yes Simonneau et al., 200841
TRIUMPH Bosentanþ inhaled treprostinil Yes McLaughlin et al., 201042
Sildenafilþ inhaled treprostinil No McLaughlin et al., 201042
PATENT ERAs/non-intravenous prostanoidsþ riociguat Yes Ghofrani et al., 201323
SERAPHIN PDE5i/non-intravenous prostanoidsþmacitentan Yes Pulido et al., 201321
AMBITION First-line ambrisentanþ tadalafil Yes Galie` et al., 201543
STEP Bosentanþ inhaled iloprost Yes McLaughlin et al., 200644
GRIPHON PDE5i/ERAsþ selexipag Yes McLaughlin et al., 201845
MERIT-1 PDE5iþmacitentan Yes Ghofrani et al., 201734
FREEDOM-C ERAs/non-intravenous prostanoidsþ oral treprostinil No Tapson et al., 201246
PHIRST Bosentanþ tadalafil No Galie` et al., 200919
COMPASS-2 Sildenafilþ bosentan No McLaughlin et al., 201447
NCT00323297 Bosentanþ sildenafil No Vizza et al., 201720
BREATHE-2 Epoprostenolþ bosentan No Humbert et al., 200448
PATENT-PLUS Sildenafilþ riociguat No Galie` et al., 201549
ERA, endothelin receptor analog; PDE5i, phosphodiesterase 5 inhibitor.
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to ambrisentan were US patients enroled in an open-label
study of sitaxsentan in PAH and switched at study closure
because sitaxsentan did not receive Food and Drug
Administration (FDA) approval.30 Patients in studies of
switching between PDE5i did so due to drug-related
AEs,31 the desire for greater adherence and convenience,32,33
as well as potentially lower costs and higher quality of life.33
The SITAR study assessed safety and patient satisfaction
after switching from sildenafil to tadalafil, and demonstrated
that tadalafil was well tolerated with improved convenience
for patients.32 Other studies have also supported these find-
ings demonstrating tolerance and reduced deterioration.31,33
Current treatment strategies in CTEPH
Pulmonary endarterectomy (PEA) is the recommended
treatment for CTEPH as it is potentially curative and can
result in the near normalization of pulmonary hemo-
dynamics. However, up to 40% of patients are ineligible
for surgery, and although balloon pulmonary angioplasty
(BPA) may be an option for some of these patients, the
remainder will require pharmacologic therapy, as will the
51% of patients undergoing PEA who experience persist-
ent/recurrent PH after surgery. Moreover, patients or
physicians may be reluctant to consider surgery, despite
the recommendations of treatment guidelines. Before the
approval of riociguat for inoperable and persistent/recurrent
CTEPH, patients with CTEPH were often prescribed drugs
approved for PAH off label.
At the time of writing, riociguat is the only approved
drug for the treatment of inoperable or persistent/recurrent
CTEPH, based on the phase 3 CHEST-1 study and its open-
label, long-term extension CHEST-2. However, the
recent phase 2 MERIT study of macitentan in patients
with inoperable CTEPH demonstrated encouraging results,
including in patients who were receiving background PDE5i
therapy (46%).34 In patients who are inoperable or have
persistent/recurrent CTEPH after PEA, and are not reach-
ing treatment goals on off-label medical therapy, switching
to riociguat is a logical treatment choice.35 WHO FC III
and 6MWD of 165–440 m were part of the definition
of unsatisfactory response to previous therapy in the
RESPITE and REPLACE clinical studies, and may also
be useful as criteria for patients with CTEPH who are not
reaching treatment goals and could benefit from switching
to riociguat.
BPA
An emerging treatment option for these patients may be
BPA, in which the pulmonary arteries are dilated using a
balloon inserted via a catheter. Although this can open
obstructed vessels and widen stenotic lesions without the
need for invasive surgery, it has no impact on the small-
vessel disease component of CTEPH or the underlying
pathophysiology.36 The ESC/ERS treatment guidelines cur-
rently give a lower class of recommendation for BPA (IIb)
than riociguat (I), and state that BPA should be performed
only in expert centers. BPA is usually performed in parallel
with underlying medical therapy, and the combination of
pharmacologic treatment with BPA has been investigated
in numerous smaller studies (Table 2); however, large-scale
randomized controlled trials (RTCs) are still required to
determine the benefit of BPA.4
Table 2. Studies of BPA combined with background medical therapy.
Study type Background therapy Patients (n)
Medical treatment
before BPA (%)
Significant
benefit Reference
Retrospective PEA 136 85 Yes Inami et al., 201450
PEA 29 100 Yes Taniguchi et al., 201451
PEA 20 75 Yes Fukui et al., 201452
PEA 170 91 Yes Inami et al., 201653
PEA 80 61 Yes Ogo et al., 201754
Observational Epoprostenol 68 100 Yes Mizoguchi et al., 201255
PEA 20 10 Yes Andreassen et al., 201356
PEA 56 80 Yes Kurzyna et al., 201757
Prospective PEA 12 100 Yes Sugimura et al., 201258
PDE5i/ERA 29 100 Yes Kataoka et al., 201259
PDE5i/prostaglandin 24 92 Yes Aoki et al., 201660
PDE5i 11 66 Yes Roik et al., 201661
PDE5i 56 Almost all Yes Olsson et al., 201762
Riociguat 123 100 Yes Wiedenroth et al., 201863
PEA 10 100 Yes Yanaka et al., 201864
BPA, balloon pulmonary angioplasty; ERA, endothelin receptor analog; PDE5i, phosphodiesterase 5 inhibitor; PEA, pulmonary endarterectomy.
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Clinical trials of switching to riociguat
RESPITE
Riociguat clinical Effects Studied in Patients with
Insufficient Treatment response to PDE5 inhibitors
(RESPITE) investigated whether it is feasible, safe, and
beneficial to replace PDE5i with riociguat. RESPITE was
a 24-week, prospective, open-label, multi-center, uncon-
trolled, phase 3b pilot study. Patients had symptomatic
PAH, and an insufficient response to stable treatment with
tadalafil or sildenafil. Additional inclusion criteria were:
WHO FC III, 6MWD 165–440m, cardiac index< 3.0 L/
min/m2, mean pulmonary arterial pressure
(mPAP)> 30mmHg, pulmonary capillary wedge
pressure 15mmHg, and PVR > 400 dynscm5.
PDE5i were stopped 1–3 days before the first dose of
riociguat to allow a PDE5i treatment-free period of at
least 24 h for sildenafil and at least 72 h for tadalafil.
The exploratory endpoints included 6MWD, N-terminal
prohormone of brain natriuretic peptide (NT-proBNP),
WHO FC, pulmonary hemodynamics, EuroQol 5
Dimensions (EQ-5D) quality of life score, clinical worsen-
ing, and safety.
Of the 61 patients enrolled in RESPITE, 51 completed
24 weeks of treatment; at baseline, 50 patients (82%) were
receiving combination therapy with ERAs. The majority of
patients in RESPITE reached the maximum dose of riociguat
after switching from PDE5i. In those patients completing
the study, mean standard deviation (SD) 6MWD increased
by þ31 63m (95% confidence interval [CI]¼ 13–49m;
P¼ 0.0010), mean SD NT-proBNP decreased by
347 1235pg/mL, a relative reduction of 22% (95%
CI¼ 5–37; P¼ 0.0170), and 28 patients (54%) had improved
WHO FC (52% to WHO FC II and 2% to WHO FC I;
P< 0.001). Hemodynamic data, available for 49 patients at
baseline and week 24, showed that mean SD PVR was
reduced by 103 296dynscm–5 (95% CI¼188–18;
P¼ 0.0184), mean SD mPAP was reduced by
2.8 8.8mm Hg, and right atrial pressure was reduced by
0.8 4.2mmHg. Mean SD cardiac index and mixed
venous oxygen saturation increased by þ0.3 0.5L/min/m2
(95% CI¼ 0.2–0.5L/min/m2; P¼ 0.0001) and þ1.0 6.3%,
respectively. A post hoc analysis indicated that at week 24,
41% of the overall population achieved a low-risk status
according to the ESC/ERS treatment guidelines risk assess-
ment (where an overall low-risk status was assumed when
> 50%of the available variablesmet the low-risk thresholds).37
The switch to riociguat was tolerated by the majority of
patients. Fifty-eight patients (95%) experienced an AE, the
most common of which were dyspepsia (n¼ 14 [23%]),
headache (n¼ 12 [20%]), and diarrhea (n¼ 11 [18%]). No
serious adverse events (SAEs) or clinical worsening events
were reported during the PDE5i treatment-free period; two
patients (3%) experienced SAEs during the first two weeks
of riociguat treatment. Two patients (3%) died (one sub-
dural hematoma and one pneumonia, both not related to
riociguat) during the study. Overall, the safety profile of
riociguat was consistent with the results of the PATENT-1
and PATENT-2 studies.
The RESPITE study was limited by the lack of a control
group, lack of blinding, and the drop-out rate (n¼ 10 [16%]),
which may have biased the analysis. To address this
potential bias, a sensitivity analysis was performed using
worst-possible values for 6MWD, WHO FC, and EQ-5D,
and the last observation carried forward for hemodynamics
to provide the most conservative view of the data.
Improvement was still in line with the overall results of the
study, but no longer statistically significant for 6MWD and
NT-proBNP; the change for WHO FC remained
significant.37
RESPITE was the first study to investigate the clinical
safety and efficacy outcomes of switching from PDE5i to rio-
ciguat in PAH, and has provided preliminary evidence that
switching may be safe, tolerable, and beneficial in patients
with PAHwith an insufficient response to PDE5i. The findings
also offer preliminary support to the hypothesis that the NO-
sGC-cGMP pathway might be optimized by riociguat.
However, given the limitations of RESPITE noted above,
larger controlled studies are needed to confirm this.
Table 3. Studies evaluating switching between other PAH-approved therapies.
Transition Drug class Reference
Sildenafil to tadalafil PDE5i Lichtblau et al., 2015;31
Frantz et al., 2014;32
Shapiro et al., 201365
Prostacyclin to iloprost Prostaglandin Channick et al., 201325
Iloprost to treprostinil Prostaglandin Bourge et al., 201326
Sitaxsentan to ambrisentan ERA Safdar, 201130
Prostacyclin to bosentan Prostaglandin to ERA Safdar, 200928
Treprostinil to sildenafil Prostaglandin to PDE5i Keogh et al., 200729
Epoprostenol to treprostinil Prostaglandin Rubenfire et al., 200727
ERA, endothelin receptor analog; PAH, Pulmonary arterial hypertension.
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REPLACE
Following the preliminary signals of improvement observed
in RESPITE, the phase 4, prospective, randomized, con-
trolled, open-label study REPLACE (Riociguat rEplacing
PDE5i Therapy evaLuated Against Continued PDE5i
thErapy; NCT02891850) was initiated and will investigate
the efficacy of riociguat as a replacement for PDE5i in
patients with PAH. Patients will be randomized to switch
to riociguat or remain on PDE5i therapy (with or without
concomitant ERAs) for 24 weeks. The primary endpoint of
the study will be satisfactory clinical response, defined as
free from clinical worsening and fulfilling at least two of
the following criteria: an increase in 6MWD 10%
or 30 m from baseline to week 24; WHO FC I/II at
week 24; or a reduction in NT-proBNP 30% from baseline
to week 24. Secondary outcomes include 6MWD, NT-
proBNP, WHO FC, REVEAL risk score, and clinical wor-
sening. REPLACE commenced in December 2016 and is
estimated to finish in August 2019.
CTEPH Early Access Study
The CTEPH Early Access Study assessed the safety and
tolerability of riociguat in 300 patients in real-world clinical
practice. This open-label, uncontrolled, phase 3b, long-term
surveillance study included patients with inoperable or per-
sistent/recurrent CTEPH after PEA, who were not satisfac-
torily treated, or treatment-naı¨ve and could not participate
in another CTEPH trial. The study provided early access to
riociguat before market launch and consisted of three
phases: an eight-week dose-adjustment phase; a mainten-
ance phase until riociguat was available in a patient’s
respective country; and a safety follow-up phase. All
patients underwent a PDE5i/ERA/PCA treatment-free
period of at least 72 h before initiating riociguat.
Concomitant treatment with an ERA or PCA was permitted
after the dose-adjustment phase.
Of the 300 patients enrolled in the study, 84 (28%)
switched to riociguat from other single or combination
PAH-targeted therapies, with a median treatment-free
period of four days (range¼ 3–74 days). Fifty-eight patients
(19%) previously received PDE5i (most frequently sildenafil
[14%]), 44 patients (15%) ERAs (most commonly bosentan
[12%]), and seven patients PCAs (most commonly iloprost
[2%]). Twenty-four patients (8%) received dual (n¼ 23
[8%]) or triple (n¼ 1 [<1%]) combination therapy before
switching.
The safety and tolerability of riociguat was similar
between patients who switched from other PAH-targeted
therapies and those who were treatment-naı¨ve, and was
comparable with that of the CHEST-1 and CHEST-2 stu-
dies. During the PDE5i/ERA/PCA treatment-free period,
AEs were experienced by 11 patients (13%), eight of
which were mild in severity. Two patients experienced
SAEs during the treatment-free period (syncope and hospi-
talization due to septicemia), both of which resolved.
Overall, other PAH-targeted therapies were initiated or
restarted by 42 patients (14%), the majority due to worsen-
ing CTEPH. In patients who switched from prior PAH-tar-
geted therapy, 17 patients (20%) started an ERA and
one patient (1%) started a PCA during the maintenance
phase. Two patients (2%) restarted PDE5i treatment on
the same day as discontinuing riociguat. Overall, 38 patients
(13%) discontinued riociguat during the study, with AEs
being the most frequent reason (n¼ 14), and four patients
discontinued riociguat treatment during the safety follow-up
phase.
Assessment of 6MWD was optional during the study;
therefore, data were not available for all patients. In
switched patients, mean SD baseline 6MWD was
389 87m. At week 12, mean SD change from baseline
wasþ 28 39m (n¼ 32). The percentage of switched
patients in WHO FC I/II/III/IV at baseline was 2%
(n¼ 84). After 12 weeks of treatment, WHO FC had
improved/stabilized/worsened in 21/76/3% (n¼ 70).
Case studies of switching to riociguat
In addition to preliminary clinical trial data, some case
study reports and retrospective analyses have also provided
initial data around switching to riociguat in clinical settings
(Table 4). For example, a retrospective analysis by Davey
et al. of 12 patients with PH showed that switching to rio-
ciguat led to an increase in cardiac index by the Fick method
of 0.41 0.16L/min/m2 (P¼ 0.026), a concomitant decrease
in PVR from 649 103 to 524 102 dyn.s.cm5 (P¼ 0.037),
and an improvement in WHO FC from 2.8 0.01 to
2.5 0.2 (P¼ 0.018) after 12 weeks of therapy. Headache
and lowering of blood pressure were commonly reported
following the switch, but patients experiencing these side
effects did not discontinue riociguat. Weir et al. performed
an independent retrospective analysis of 31 patients with
PAH who had switched from PDE5i to riociguat. Twenty-
two patients (71%) successfully switched; in this group,
mPAP decreased from 43.7 to 38.3mmHg (P¼ 0.0285),
PVR from 7.93 to 4.6 WU (P¼ 0.0036), cardiac index
increased from 2.9 to 3.13L/min/m2 (P¼ 0.53), and
6MWD by 21m (P¼ 0.19). Nine patients (29%) did not
tolerate the switch due to worsening symptoms (78%) or
side effects (22%). Raina et al. described three patients
with PAH associated with connective tissue disease (PAH-
CTD), where the switch to riociguat from PDE5i was asso-
ciated with clinical and hemodynamic improvements, simi-
lar to those observed in patients with PAH-CTD in the
PATENT-1 and PATENT-2 studies. Yamamoto et al.
described eight patients with CTEPH who switched from
PDE5i treatment to riociguat and experienced a significant
reduction of 116.5 pg/mL SD (P¼ 0.0156) in BNP, and
improvements in mPAP, PVR, cardiac index, and partial
pressure of oxygen in arterial blood. Finally, Darocha
et al. performed a retrospective analysis of 28 patients
with inoperable CTEPH who switched from sildenafil to
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riociguat. Patients demonstrated reductions in PVR, mPAP,
and increased cardiac output.38
The data from these case studies suggest that switching to
riociguat has been considered in the clinical setting, with the
suggestion of therapeutic efficacy, although the current role
of this therapeutic modality in the treatment algorithm is
not yet defined.
Non-interventional studies
The EXPERT registry (NCT02092818) has collected evi-
dence from real-world clinical practice on patients with
PAH or CTEPH receiving riociguat. Safety data from
EXPERT on patients with PAH or CTEPH who switched
from other PAH-targeted therapies indicated that tolerabil-
ity was similar between switched and treatment-naı¨ve
patients, and that AEs and SAEs in switched patients were
consistent with the known safety profile of riociguat.39
The retrospective chart review study CAPTURE enrolled
125 patients with PAH, or inoperable or persistent/recurrent
CTEPH, who switched to riociguat from another PH-tar-
geted medical therapy. The aim of the study was to under-
stand real-world procedures for switching to riociguat, and
the results suggest that switching to riociguat from other
PH-targeted therapies appears to be feasible in the context
of current label recommendations.
How to switch within the NO pathway
Given the limited existing evidence and the lack of a recom-
mendation for switching in published guidelines, we would
not encourage switching until randomized data supporting
this strategy are available. As noted above, the rationale
for switching from PDE5i to riociguat is to optimize the
NO-sGC-cGMP signaling pathway. Concomitant adminis-
tration of riociguat and PDE5i exerts an additive effect on
systemic blood pressure, and clinically significant hypoten-
sion can occur. Concomitant use of all PDE5i, or non-spe-
cific PDE5i and riociguat, is contraindicated and a PDE5i
treatment-free period must be initiated before switching
to riociguat. The recommended PDE5i treatment-free
periods, as used in the RESPITE and REPLACE studies,
are based on the pharmacokinetics of sildenafil and tadalafil,
and data from real-world clinical practice. Sildenafil should
be discontinued for at least 24 h and tadalafil should be
discontinued for at least 48 h before administering riociguat.
In addition, it is recommended to monitor for signs and
symptoms of hypotension on initiation. Should a patient
need to be switched from riociguat to a PDE5i, riociguat
must be discontinued at least 24 h before initiation of the
PDE5i, and the patient should be monitored for signs and
symptoms of hypotension upon initiation of the new
therapy.40
If individual clinicians wish to attempt a switch to rioci-
guat based on their medical judgment, patient enrolment in
the ongoing REPLACE study should be considered.
We suggest that possible candidates for a switch include:
patients who have not reached a low-risk profile (e.g. one
or two intermediate-risk characteristics) but who do not
have any high-risk characteristics by ESC/ERS criteria, or
patients with a REVEAL risk score of 6–8 who are stable/
not declining rapidly for several months. Indeed, prelimin-
ary data from RESPITE suggest that patients with lower
PVR and right arterial pressure, and higher 6MWD at base-
line, were more likely to respond to a switch. Any decision
regarding a change in therapy should be based on individual
clinical status and/or the AEs of any previously adminis-
tered therapy. If switching to riociguat from other PAH-
specific drugs is considered appropriate or necessary, the
decision regarding the execution of such a switch can only
be made at the discretion of the experienced treating PH
physician after discussion with the patient. REPLACE has
the potential to provide further data on when switching
might be considered over sequential combination therapy
in patients not meeting treatment goals.
Expert opinion/clinical perspectives
Early, limited clinical evidence from RESPITE and case
series data indicate that switching to riociguat may be a
viable treatment option in carefully selected patients with
PH who are not achieving treatment goals with their current
regimen. There are, however, no RCTs comparing switching
with either continued therapy or sequential combination
therapy. Further trials are taking place that may determine
whether switching will become a goal-oriented treatment
strategy for minimizing risk in patients with PAH, and
this may identify where switching could be placed in the
PAH treatment algorithm. Although switching to riociguat
may be of benefit to some patients, it is important to note
that it is not possible to identify responders upfront.
Previous data indicated that switching would be less appro-
priate in patients with deteriorating and advanced symp-
toms, and these patients are candidates for treatment with
sequential combination therapy and/or parenteral prosta-
noids, as recommended in the ERS/ESC guidelines. We rec-
ommend that a patient’s risk is assessed by either REVEAL
score or ERS/ESC risk criteria when making treatment
decisions.
Conclusion
Data on switching between PAH-approved therapies in
patients with PAH or CTEPH are still limited. The studies
reviewed here summarize the available evidence and prac-
tical experience in a situation where there is no formal
protocol or recommendation available for switching. In
line with the recommendation of goal-oriented therapy to
keep patients at a low-risk status, switching may present a
potential additional strategy to sequential combination ther-
apy in low- to intermediate-risk patients, keeping the option
of adding a third drug class for a later stage in the disease
Pulmonary Circulation Volume 10 Number 1 | 9
course. There are no data to support switching between
therapies for patients undergoing triple drug therapy.
The studies discussed here suggest that switching to rio-
ciguat may be safe, tolerable, and beneficial in patients with
PAH who have an insufficient response to PDE5i, and in
patients with CTEPH who are receiving off-label treatment.
However, additional data from RCTs are needed to deter-
mine if this strategy is an effective approach to the manage-
ment of patients with PAH and CTEPH.
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